ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

vadadustat

Also written as “Vadadustat”, “AKB-6548” and “MT-6548”.

Its studies are mostly in Anemia · Renal Insufficiency, Chronic, led by 2 companies.

Drug pageVadadustat: every studyAll 40 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 4, 201636 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akebia Therapeutics320 open or runningphase 3since Jan 4, 2016Nov 5, 2010none ahead
Tanabe Pharmaits history only40 open or runningphase 3since Oct 30, 2017Oct 30, 2017none ahead

Also a collaborator on its studies: Otsuka.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Akebia Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 12 earlier studies, Nov 5, 2010 to Sep 2, 2016.

  1. Dec 9, 2015Named vadadustatINNProposed as its International Nonproprietary Name in WHO's List 114 · before, AKB-6548, MT-6548
  2. Feb 13, 20172 phase 2 studies in AnemiaNCT03054350, NCT03054337
  3. May 3, 2017Phase 2 study in AnemiaNCT03140722 · 2 enrolled · United States
  4. Aug 4, 2017Phase 3 study in AnemiaNCT03242967 · United States
  5. Jun 12, 2018Phase 1 study in HealthyNCT03639155 · 50 enrolled · United States
  6. Aug 31, 2018Phase 1 study in HealthyNCT03657290 · 54 enrolled · United States
  7. Dec 3, 2018Phase 2 study in AnemiaNCT03799627 · 175 enrolled · United States
  8. Dec 27, 20185 phase 1 studiesNCT03801759, NCT03801746, NCT03801733 and 2 more
  9. Jun 18, 2019Phase 1 study in AnemiaNCT03992066 · 46 enrolled · United States
  10. Mar 5, 2020Phase 1 study in Healthy VolunteersNCT04299633 · 54 enrolled · Canada
  11. Mar 16, 2020Phase 3 study in AnemiaNCT04313153 · 319 enrolled · United States, Czechia, Hungary and more
  12. Nov 2, 2020Phase 2 study in Renal Insufficiency, ChronicNCT04707573 · 22 enrolled · United States
  13. Jan 12, 2021Phase 3 study in AnemiaNCT04707768 · 456 enrolled · United States
  14. Sep 28, 20212 phase 3 studies in AnemiaNCT05082584, NCT05082571
  15. Mar 27, 2025Phase 3 study in Renal Insufficiency, ChronicNCT06901505 · 353 enrolled · United States

TargetBeta

“Egl nine homolog 1 inhibitor; Egl nine homolog 3 inhibitor; Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
roxadustatruleAstellas Pharmaphase 447
daprodustatruleGlaxoSmithKlinephase 333

Studies

All 32 Akebia Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06901505Renal Insufficiency, Chronic · United States3CompletedAug 12, 2026353
NCT05082584Anemia · United States3WithdrawnJul 20260
NCT05082571Anemia · United States3WithdrawnJul 20260
NCT04707768Anemia · United States3CompletedJan 6, 2023456
NCT04707573Renal Insufficiency, Chronic · United States2CompletedSep 24, 201022
NCT04313153Anemia · United States, Czechia, Hungary and more3CompletedNov 26, 2021319
NCT04299633Healthy Volunteers · Canada1CompletedAug 2, 202054
NCT03992066Anemia · United States1CompletedMay 5, 202046
NCT03801759Drug Interaction Potentiation · Canada1CompletedSep 30, 201862
NCT03801746Drug Interaction Potentiation · Canada1CompletedAug 15, 201840
NCT03801733Drug Interaction Potentiation · Canada1CompletedNov 24, 2018134
NCT03799848Hepatic Impairment · United States1CompletedOct 18, 201824
NCT03789032Drug Interaction Potentiation · Canada1CompletedNov 9, 201820
NCT03799627Anemia · United States2CompletedJun 5, 2020175
NCT03657290Healthy · United States1CompletedOct 16, 201854
NCT03639155Healthy · United States1CompletedMay 23, 201850
NCT03242967Anemia · United States3WithdrawnFeb 12, 20180
NCT03140722Anemia · United States2TerminatedMar 21, 20182
NCT03054350Anemia · Japan2CompletedOct 24, 201760
NCT03054337Anemia · Japan2CompletedJul 4, 201751
NCT02892149Anemia · United States, Argentina, Australia and more3CompletedJan 16, 20203,554
NCT02865850Anemia · United States, Argentina, Brazil and more3CompletedJan 31, 2020369
NCT02680574Anemia · United States, Argentina, Australia and more3CompletedJun 18, 20201,725
NCT02648347Anemia · United States, Argentina, Australia and more3CompletedJun 4, 20201,751
NCT02502500Healthy Volunteers1CompletedJul 201512
NCT02412449Anemia · United States1CompletedApr 201518
NCT02327546Anemia · United States1CompletedDec 201410
NCT02260193Anemia · United States2CompletedJul 22, 201594
NCT02062203Anemia · United States1CompletedApr 201450
NCT01906489Anemia · United States2CompletedSep 3, 2014210
NCT01381094Anemia · United States2CompletedFeb 16, 201293
NCT01235936Anemia · United States2CompletedApr 13, 201110

How it is read

Names in the registry

  • “Vadadustat”, 19 entries
  • “AKB-6548”, 8 entries
  • “MT-6548”, 4 entries
  • “vadadustat”, 4 entries
  • “vadadustat reference tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.